-
Uncategorized2 months ago
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral...
-
Uncategorized2 months ago
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts...
-
Uncategorized2 months ago
FDA flags concerns for AstraZeneca’s camizestrant, Truqap ahead of advisory committee meeting
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such...
-
Uncategorized2 months agoFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold...
-
Uncategorized2 months agoSTAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I started the morning...
-
Uncategorized2 months agoUS tariffs: How will the latest changes impact drug discovery?
Trump’s global tariffs have been ruled illegal by the Supreme Court – but what, if any, effect will the judgment have on pharmaceutical imports? Diana Turner...
-
Uncategorized2 months ago
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.
-
Uncategorized2 months ago
AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment...
-
Uncategorized2 months ago
FDA claims trial ‘manipulation’ tainted approval of ChemoCentryx drug
FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug
-
Uncategorized2 months ago
FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results...
